Pangaea Oncology, S.A. (PANG.MC)
EUR 1.76
(0.0%)
EUR 1.76
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.39 Million | -3.67 Million | -2.5 Million | -1.91 Million | -2.39 Million | -2.16 Million |
| Net Income | -3.5 Million | -2.83 Million | -1.09 Million | -1.9 Million | -4.98 Million | -2.12 Million |
| Depreciation & Amortization | 1.81 Million | 1.24 Million | 992.28 Thousand | 2.4 Million | 3.08 Million | 2.52 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 825.19 Thousand | -79.19 Thousand | -1.46 Million | -427.54 Thousand | -882.69 Thousand | -306.16 Thousand |
| Other non-cash items | -2.07 Million | -1.99 Million | -926.73 Thousand | -1.98 Million | 389.06 Thousand | -2.25 Million |
| Investing Cash Flow | -1.57 Million | -745.57 Thousand | -797.48 Thousand | -190.18 Thousand | -20.3 Thousand | -85.66 Thousand |
| Investments in PPE | -291.35 Thousand | -20.08 Thousand | -29.67 Thousand | -70.96 Thousand | -984.00 | -27.33 Thousand |
| Acquisitions | -1.53 Million | -120.05 Thousand | -387 Thousand | -150 Thousand | - | 2524.00 |
| Investment purchases | - | -605.43 Thousand | -380.8 Thousand | - | -75.03 Thousand | -310.67 Thousand |
| Sales/Maturities of investments | 246.93 Thousand | - | 2951.00 | 30.77 Thousand | 55.71 Thousand | 252.34 Thousand |
| Other Investing Activities | -35.33 Thousand | - | -2951.00 | - | - | -2524.00 |
| Financing Cash Flow | -1.05 Million | 9.5 Million | 5.07 Million | 2.03 Million | 2.09 Million | 2.6 Million |
| Debt repayment | -356.45 Thousand | -1.72 Million | -1.76 Million | -3.48 Million | -1.48 Million | -1.33 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2.22 Million | - | -16.39 Thousand | - | - | - |
| Common Stock Issuance | 61.99 Thousand | 11.22 Million | 6.4 Million | - | 1.59 Million | 2.38 Million |
| Other Financing Activities | 757.85 Thousand | - | 453.03 Thousand | 5.52 Million | 1.98 Million | 1.55 Million |
| Accounts receivables | 385.83 Thousand | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -130.81 Thousand | 78.81 Thousand | -36.41 Thousand | -182.66 Thousand | 8409.00 | -105.66 Thousand |
| Other working capital | 570.17 Thousand | -158 Thousand | -1.43 Million | -244.88 Thousand | -891.1 Thousand | -200.49 Thousand |
| Cash at beginning of period | 7.1 Million | 2.02 Million | 251.47 Thousand | 339.63 Thousand | 667.42 Thousand | 314.31 Thousand |
| Cash at end of period | 1.38 Million | 7.1 Million | 2.02 Million | 251.47 Thousand | 339.63 Thousand | 667.42 Thousand |
| Capital Expenditure | -291.35 Thousand | -20.08 Thousand | -29.67 Thousand | -70.96 Thousand | -984.00 | -27.33 Thousand |
| Effect of forex changes on cash | - | - | -10.02 Thousand | -21.15 Thousand | -996.00 | 140.00 |
| Net cash flow / Change in cash | -5.72 Million | 5.08 Million | 1.76 Million | -88.15 Thousand | -327.78 Thousand | 353.1 Thousand |
| Free Cash Flow | -2.68 Million | -3.69 Million | -2.52 Million | -1.98 Million | -2.39 Million | -2.19 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.86 Million | -3.5 Million | -1.86 Million | -459.78 Thousand | -459.78 Thousand | -2.83 Million |
| Depreciation & Amortization | 557.82 Thousand | 1.81 Million | 557.82 Thousand | 349.81 Thousand | 349.81 Thousand | 1.24 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 57.05 Thousand | 825.19 Thousand | 57.05 Thousand | 3065.00 | 3065.00 | -79.19 Thousand |
| Other non-cash items | 514.86 Thousand | -2.07 Million | 514.86 Thousand | -353.17 Thousand | -353.17 Thousand | -1.99 Million |
| Investing Cash Flow | -712.63 Thousand | -1.57 Million | -712.63 Thousand | -76.75 Thousand | -76.75 Thousand | -745.57 Thousand |
| Investments in PPE | -53.27 Thousand | -291.35 Thousand | -53.27 Thousand | -74.73 Thousand | -74.73 Thousand | -20.08 Thousand |
| Acquisitions | -767.17 Thousand | -1.53 Million | -767.17 Thousand | - | - | -120.05 Thousand |
| Investment purchases | - | - | - | - | - | -605.43 Thousand |
| Sales/Maturities of investments | - | 246.93 Thousand | - | - | - | - |
| Other Investing Activities | 107.82 Thousand | - | 107.82 Thousand | -2018.00 | -2018.00 | - |
| Financing Cash Flow | 378.86 Thousand | -1.05 Million | 378.86 Thousand | -1.25 Million | -1.25 Million | 9.5 Million |
| Debt repayment | - | -356.45 Thousand | - | - | - | -1.72 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 3466.00 | -2.22 Million | - | -1.11 Million | -1.11 Million | - |
| Common Stock Issuance | - | 61.99 Thousand | - | - | - | 11.22 Million |
| Other Financing Activities | 375.4 Thousand | 757.85 Thousand | 378.86 Thousand | -134.65 Thousand | -134.65 Thousand | - |
| Accounts receivables | 178.59 Thousand | - | 178.59 Thousand | 14.32 Thousand | 14.32 Thousand | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 80.59 Thousand | -130.81 Thousand | 80.59 Thousand | -146 Thousand | -146 Thousand | 78.81 Thousand |
| Other working capital | -202.13 Thousand | - | -202.13 Thousand | 134.74 Thousand | 134.74 Thousand | -158 Thousand |
| Cash at beginning of period | - | 7.1 Million | - | - | - | 2.02 Million |
| Cash at end of period | -1.07 Million | 1.38 Million | -1.07 Million | -1.78 Million | -1.78 Million | 7.1 Million |
| Capital Expenditure | -53.27 Thousand | -291.35 Thousand | -53.27 Thousand | -74.73 Thousand | -74.73 Thousand | -20.08 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.07 Million | -5.72 Million | -1.07 Million | -1.78 Million | -1.78 Million | 5.08 Million |
| Free Cash Flow | -791.95 Thousand | -2.68 Million | -791.95 Thousand | -534.81 Thousand | -534.81 Thousand | -3.69 Million |
ATH-PA
603055
007810
HRMNYCP
3221
ASTRAZEN